Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Net Assets
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has net assets worth CN¥2.12 Billion CNY (≈ $309.74 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.39 Billion ≈ $349.83 Million USD) and total liabilities (CN¥273.93 Million ≈ $40.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.12 Billion |
| % of Total Assets | 88.54% |
| Annual Growth Rate | 15.26% |
| 5-Year Change | -3.33% |
| 10-Year Change | 142.45% |
| Growth Volatility | 42.8 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual net assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025. For live valuation and market cap data, see 688505 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.12 Billion ≈ $309.74 Million |
-8.18% |
| 2024-12-31 | CN¥2.31 Billion ≈ $337.33 Million |
-2.26% |
| 2023-12-31 | CN¥2.36 Billion ≈ $345.13 Million |
+4.68% |
| 2022-12-31 | CN¥2.25 Billion ≈ $329.69 Million |
+2.90% |
| 2021-12-31 | CN¥2.19 Billion ≈ $320.41 Million |
+9.02% |
| 2020-12-31 | CN¥2.01 Billion ≈ $293.91 Million |
+115.24% |
| 2019-12-31 | CN¥933.15 Million ≈ $136.55 Million |
-6.05% |
| 2018-12-31 | CN¥993.28 Million ≈ $145.35 Million |
+11.29% |
| 2017-12-31 | CN¥892.48 Million ≈ $130.60 Million |
+2.23% |
| 2016-12-31 | CN¥873.05 Million ≈ $127.76 Million |
+14.00% |
| 2015-12-31 | CN¥765.84 Million ≈ $112.07 Million |
+13.22% |
| 2014-12-31 | CN¥676.42 Million ≈ $98.98 Million |
+19.52% |
| 2013-12-31 | CN¥565.92 Million ≈ $82.81 Million |
+117.57% |
| 2012-12-31 | CN¥260.11 Million ≈ $38.06 Million |
+29.37% |
| 2011-12-31 | CN¥201.07 Million ≈ $29.42 Million |
+19.18% |
| 2010-12-31 | CN¥168.71 Million ≈ $24.69 Million |
+0.20% |
| 2009-12-31 | CN¥168.37 Million ≈ $24.64 Million |
+121.88% |
| 2008-12-31 | CN¥75.88 Million ≈ $11.10 Million |
+6.82% |
| 2007-12-31 | CN¥71.04 Million ≈ $10.40 Million |
-30.14% |
| 2006-12-31 | CN¥101.70 Million ≈ $14.88 Million |
-17.81% |
| 2005-12-31 | CN¥123.73 Million ≈ $18.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67621736800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥676.22 Million | 31.95% |
| Other Components | CN¥1.44 Billion | 68.05% |
| Total Equity | CN¥2.12 Billion | 100.00% |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Swissquote Group Holding SA
SW:SQN
|
$734.85 Million |
|
China Fortune Land Development Co Ltd
SHG:600340
|
$734.94 Million |
|
Shenzhen Hirisun Technology Inc
SHE:300277
|
$735.02 Million |
|
Jiangsu Huaxicun Co Ltd
SHE:000936
|
$735.12 Million |
|
Baotailong New Materials Co Ltd
SHG:601011
|
$734.44 Million |
|
Hwang Chang General Contractor Co Ltd
TW:2543
|
$734.35 Million |
|
Orrstown Financial Services Inc
NASDAQ:ORRF
|
$734.25 Million |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
$734.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,304,567,412 to 2,116,293,902, a change of -188,273,510 (-8.2%).
- Net loss of 157,439,498 reduced equity.
- Dividend payments of 31,097,163 reduced retained earnings.
- Other comprehensive income decreased equity by 123,323,279.
- Other factors increased equity by 123,586,430.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-157.44 Million | -7.44% |
| Dividends Paid | CN¥31.10 Million | -1.47% |
| Other Comprehensive Income | CN¥-123.32 Million | -5.83% |
| Other Changes | CN¥123.59 Million | +5.84% |
| Total Change | CN¥- | -8.17% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.05x to 3.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | CN¥0.17 | CN¥7.14 | x |
| 2006-12-31 | CN¥0.14 | CN¥7.14 | x |
| 2007-12-31 | CN¥0.10 | CN¥7.14 | x |
| 2008-12-31 | CN¥0.10 | CN¥7.14 | x |
| 2009-12-31 | CN¥0.19 | CN¥7.14 | x |
| 2010-12-31 | CN¥0.20 | CN¥7.14 | x |
| 2011-12-31 | CN¥0.24 | CN¥7.14 | x |
| 2012-12-31 | CN¥0.31 | CN¥7.14 | x |
| 2013-12-31 | CN¥0.62 | CN¥7.14 | x |
| 2014-12-31 | CN¥0.71 | CN¥7.14 | x |
| 2015-12-31 | CN¥0.79 | CN¥7.14 | x |
| 2016-12-31 | CN¥0.91 | CN¥7.14 | x |
| 2017-12-31 | CN¥0.95 | CN¥7.14 | x |
| 2018-12-31 | CN¥1.06 | CN¥7.14 | x |
| 2019-12-31 | CN¥1.01 | CN¥7.14 | x |
| 2020-12-31 | CN¥2.03 | CN¥7.14 | x |
| 2021-12-31 | CN¥2.10 | CN¥7.14 | x |
| 2022-12-31 | CN¥2.19 | CN¥7.14 | x |
| 2023-12-31 | CN¥2.28 | CN¥7.14 | x |
| 2024-12-31 | CN¥2.22 | CN¥7.14 | x |
| 2025-12-31 | CN¥2.02 | CN¥7.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.96%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.13x
- Recent ROE (-7.44%) is below the historical average (2.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -25.18% | -150.90% | 0.14x | 1.19x | CN¥-42.41 Million |
| 2006 | -22.12% | -111.47% | 0.14x | 1.46x | CN¥-31.99 Million |
| 2007 | -42.18% | -118.55% | 0.19x | 1.86x | CN¥-36.56 Million |
| 2008 | -31.80% | -73.15% | 0.20x | 2.15x | CN¥-30.76 Million |
| 2009 | -5.39% | -11.82% | 0.21x | 2.20x | CN¥-20.89 Million |
| 2010 | 2.64% | 3.98% | 0.30x | 2.18x | CN¥-10.24 Million |
| 2011 | 18.13% | 23.02% | 0.37x | 2.11x | CN¥13.82 Million |
| 2012 | 23.81% | 22.86% | 0.43x | 2.41x | CN¥30.84 Million |
| 2013 | 16.37% | 20.97% | 0.56x | 1.41x | CN¥33.95 Million |
| 2014 | 18.17% | 25.11% | 0.57x | 1.27x | CN¥53.16 Million |
| 2015 | 17.43% | 22.04% | 0.57x | 1.39x | CN¥54.46 Million |
| 2016 | 16.44% | 22.30% | 0.55x | 1.33x | CN¥54.35 Million |
| 2017 | 8.63% | 15.13% | 0.43x | 1.31x | CN¥-11.95 Million |
| 2018 | 11.42% | 15.11% | 0.51x | 1.49x | CN¥13.92 Million |
| 2019 | 24.41% | 22.09% | 0.66x | 1.68x | CN¥134.21 Million |
| 2020 | 8.19% | 19.75% | 0.33x | 1.24x | CN¥-36.43 Million |
| 2021 | 9.73% | 18.71% | 0.41x | 1.27x | CN¥-6.00 Million |
| 2022 | 6.11% | 13.38% | 0.35x | 1.32x | CN¥-87.71 Million |
| 2023 | 4.61% | 12.77% | 0.30x | 1.22x | CN¥-127.13 Million |
| 2024 | 1.72% | 5.60% | 0.27x | 1.12x | CN¥-190.72 Million |
| 2025 | -7.44% | -22.96% | 0.29x | 1.13x | CN¥-369.07 Million |
Industry Comparison
This section compares Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) | CN¥2.12 Billion | -25.18% | 0.13x | $734.50 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more